MetaCap

ClearPoint Neuro (CLPT) vs Neuropace (NPCE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neuropace (NPCE) has outperformed ClearPoint Neuro (CLPT) over the past year, losing 44.6% versus a loss of 50.0%. Over five years, NPCE leads with a -32.8% price change compared with -50.0% for CLPT. Neuropace is the larger company by market cap ($273.9 million vs $221.5 million), about 1.2 times the size.

Neuropace converts more of its revenue into profit, with a net margin of -21.5% versus -69.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLPT-50.00%NPCE-44.60%
+45%-5%-55%
Nov 21, 20251 yearNov 20, 2026
CLPT-51.78%NPCE-32.91%
+100%+1%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLPT versus NPCE key metrics
MetricCLPTNPCE
Share price$6.91$7.95
Market cap$221.49M$273.89M
1-day change-5.47%-2.33%
YTD return-49.49%-48.51%
1-year return-50.00%-44.60%
5-year return-50.04%-32.80%
EPS (TTM)$-1.21$-0.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$36.97M$99.99M
Revenue growth (YoY)+17.78%+25.13%
Net income (latest FY)$-25.54M$-21.46M
Gross margin61.38%77.23%
Operating margin-65.36%-16.34%
Net margin-69.08%-21.47%
52-week high$19.63$19.60
52-week low$6.85$5.46
Distance from 52-week high-64.80%-59.44%
Analyst consensusnonebuy
Avg. price target upside+211.14%+53.71%
Average volume701.64K270.76K
Shares outstanding32.05M34.45M
Employees172216
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Neuropace is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -69.1 cents for ClearPoint Neuro.
  • Neuropace grew revenue faster in its latest fiscal year (+25.13% vs +17.78%).

About ClearPoint Neuro

CLPT stock →

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.

Health Care · Medical/Dental Instruments · 172 employees

About Neuropace

NPCE stock →

NeuroPace, Inc. operates as a medical device company in the United States.

Health Care · Medical/Dental Instruments · 216 employees

CLPT vs NPCE FAQ

Which is bigger, ClearPoint Neuro or Neuropace?

Neuropace (NPCE) is larger, with a market capitalization of $273.89M compared with $221.49M for ClearPoint Neuro (CLPT).

Which stock has performed better over the past year, CLPT or NPCE?

NPCE returned -44.60% over the past 12 months, compared with -50.00% for CLPT (price return, excluding dividends). Past performance does not predict future results.

Are ClearPoint Neuro and Neuropace in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons